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Abstract
Background Overactive bladder (OAB) is highly pre-
valent and is associated with considerable morbidity and
reduced health-related quality of life. b3-adrenergic
receptor (b3-AR) stimulation is a novel alternative to an-
timuscarinic therapy for OAB.
Objective The objective of this analysis was to assess the
cost effectiveness of the b3-AR agonist mirabegron relative
to tolterodine extended release (ER) in patients with OAB
from a UK National Health Service (NHS) perspective.
Methods A Markov model was developed to simulate the
management, course of disease, and effect of complications
in OAB patients over a period of 5 years. Transition
probabilities for symptom severity levels and probabilities
of adverse events were estimated from the results of the
randomised, double-blind SCORPIO trial in 1,987 patients
with OAB. Other model inputs were derived from the lit-
erature and on assumptions based on clinical experience.
Results Total 5-year costs per patient were £1,645.62 for
mirabegron 50 mg/day and £1,607.75 for tolterodine ER
4 mg/day. Mirabegron was associated with a gain of 0.009
quality-adjusted life-years (QALYs) with an additional cost
of £37.88. The resulting incremental cost-effectiveness
ratio (ICER) was £4,386/QALY gained. In deterministic
sensitivity analyses in the general OAB population and
several subgroups, ICERs remained below the generally
accepted willingness-to-pay (WTP) threshold of £20,000/
QALY gained. The probability of mirabegron 50 mg being
cost effective relative to tolterodine ER 4 mg was 89.4 %
at the same WTP threshold.
Conclusions Mirabegron 50 mg/day is likely to be cost
effective compared with tolterodine ER 4 mg/day for adult
patients with OAB from a UK NHS perspective.
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Key Points
Overactive bladder (OAB) is a common condition
that increases in prevalence with age and has a
significant negative impact on quality of life.
For the past 40 years, antimuscarinic agents have
been the mainstay of therapy for OAB; however,
unmet efficacy expectations and side effects,
particularly dry mouth, limit persistence with
antimuscarinic therapy.
Recently, an alternative to antimuscarinic agents has
received marketing authorisation; the b3-adrenergic
receptor agonist mirabegron is associated with at
least similar efficacy to most antimuscarinic
therapies and also has a lower incidence of dry
mouth.
No economic analyses of mirabegron compared to
antimuscarinic agents in the treatment of OAB have
been performed; therefore, we developed a model to
analyse the cost effectiveness of mirabegron 50 mg/
day relative to currently available antimuscarinic
agents for the treatment of OAB from a UK National
Health Service perspective.
The model captured the effects of variations in
symptom severity over time on quality of life and the
influence of treatment discontinuation and switch on
costs and health outcomes, as well as direct
treatment costs.
Compared to tolterodine extended release 4 mg,
mirabegron 50 mg was cost effective, with an
approximately 90 % probability of cost effectiveness
at a willingness-to-pay threshold of £20,000.
1 Introduction
Overactive bladder (OAB) is a symptom-defined condition
characterised by urinary urgency, usually with urinary
frequency and nocturia, and sometimes with urgency
incontinence [1]. Urinary urgency is particularly bother-
some for persons with OAB [2]. OAB is highly prevalent,
with a frequency that increases with age. An estimation
model based on sex- and age-stratified prevalence data and
International Continence Society definitions [3] suggested
that the overall prevalence of OAB was 10.7 % in 2008 and
predicted an increase of 20.1 %, from 455 to 546 million,
by the year 2018 [4]. This followed earlier data from a
population-based survey based on 16,776 interviews in six
European countries that showed an overall prevalence of
OAB symptoms of 16.6 % in persons aged C40 years [5].
Patients with OAB have decreased health-related quality
of life (HRQoL), including health-related work impair-
ment, depression and sexual/relationship difficulties [2, 6,
7]. Anxiety and depression are strongly associated with
OAB [7], and patients report significant social, psycho-
logical, occupational, domestic and physical stigma [8].
The prevalence of OAB and its effects on HRQoL means
that effective therapy is needed.
Treatment options for OAB include conservative man-
agement (lifestyle advice, bladder training, etc.), followed
by drug therapy and surgery where required; the primary
pharmacological option has traditionally been muscarinic
receptor antagonist therapy (antimuscarinic drugs; e.g.
oxybutynin, tolterodine and solifenacin) [9–11]. These
inhibit abnormal detrusor contractions in the bladder, but
also inhibit muscarinic receptors elsewhere in the body,
such as the salivary glands, tear ducts, brain and heart, to
varying degrees [12]. This non-specificity results in
adverse events, the most common and troublesome of
which are dry mouth, blurred vision and constipation [12,
13]. Adverse events, together with unmet efficacy expec-
tations, are the primary reasons for discontinuation of an-
timuscarinic drugs [13]. Therefore, alternative approaches
to OAB therapy have been developed and approved, the
most important of which is b3-adrenergic receptor (b3-AR)
stimulation to promote storage of urine in the bladder via
detrusor relaxation [14].
The b3-AR agonist mirabegron (Betmiga
TM; Astellas)
has been shown in phase III trials to be effective and well
tolerated in the management of OAB [15–18]. These trials
showed that mirabegron therapy significantly improves
outcomes such as the number of incontinence episodes and
micturitions per 24 h compared to placebo at 12 weeks
[15–17], and is well tolerated with sustained efficacy for up
to 12 months [18]. In trials in which patients were ran-
domised to mirabegron, tolterodine or placebo, the inci-
dence of dry mouth with tolterodine was at least threefold
that with mirabegron [15, 18]. In these trials, tolterodine
produced mean decreases in the number of incontinence
episodes and micturitions per 24 h that were not signifi-
cantly greater than those with placebo at 12 weeks, but
were similar to those with mirabegron at 12 months [15,
18].
Economic analyses comparing different treatments are
now an important factor in making decisions regarding
purchasing, pricing, reimbursement and formulary accep-
tance. To date, however, no economic analyses of mira-
begron in the treatment of OAB have been published.
Therefore, a Markov model was developed to analyse the
cost effectiveness of mirabegron 50 mg/day relative to
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currently available antimuscarinic agents for the treatment
of OAB. We describe the model in detail and report an
analysis of the cost effectiveness of mirabegron 50 mg
compared with tolterodine extended release (ER) 4 mg in
adult patients with OAB from a UK National Health Ser-
vice (NHS) payer perspective.
2 Methods
2.1 Model Overview
A Markov model was developed to simulate the thera-
peutic management, course of disease, and effect of
complications in hypothetical cohorts of OAB patients
over a 5-year period (Supplementary Figure 1). Several
existing models based on a structure developed by Kobelt
et al. [19] were already available, but were limited to a
time horizon of 1 year and did not model treatment
pathways after drop-out. Thus, differences in costs and
outcomes related to treatments used after withdrawal
could not be accurately estimated. We captured the
influence of treatment discontinuation and switch on costs
and OAB symptoms. This is particularly important
because persistence with antimuscarinic agents affects
HRQoL, health status and healthcare resource utilisation
[20]. HRQoL was assumed to be dependent on both
variations in symptoms over time and the side effects of
treatment.
2.2 The SCORPIO Trial
SCORPIO was a randomised, double-blind, parallel group,
placebo- and active-controlled phase III trial carried out in
27 countries in Europe and Australasia to compare the
efficacy and safety of mirabegron 50 and 100 mg daily
with those of placebo in patients with OAB treated over
12 weeks [15]. The co-primary endpoints were the change
from baseline to final visit in the mean number of incon-
tinence episodes and micturitions per 24 h. Assessment of
safety and tolerability was a secondary endpoint. A sec-
ondary comparison of the efficacy and safety of treatment
with tolterodine ER 4 mg daily and placebo was also
performed.
In total, 1,987 patients were randomised. Mirabegron
produced statistically significant (p \ 0.05) improvements
(adjusted mean change from baseline [95 % confidence
intervals]) compared with placebo in terms of number of
incontinence episodes per 24 h (50 mg: -1.57 [-1.79 to
-1.35]; placebo –1.17 [-1.39 to –0.95]) and number of
micturitions per 24 h (50 mg: -1.93 [-2.15 to -1.72];
placebo -1.34 [-1.55 to -1.12]). Statistically significant
improvements were also noted for other key efficacy
endpoints and HRQoL outcomes. Incidences of treatment-
emergent adverse events were similar across treatment
groups, but the incidence of dry mouth with mirabegron
50 mg was similar to placebo (2.8 and 2.6 %, respec-
tively), whereas it was more than threefold higher in
patients receiving tolterodine ER 4 mg (10.1 %) [15].
2.3 Model Description
The model was programmed to run in Microsoft Excel
2007 (Microsoft Corp., Redmond, WA, USA). The treat-
ment pathway, based on the model described above, for the
analysis is shown in Fig. 1. Transitions are shown in more
detail in Supplementary Figure 1. The model simulated
changes in symptoms (frequency of micturitions and
incontinence episodes, for which the model was run in
parallel) at monthly intervals (i.e. 60 cycles over 5 years).
Every month, patients could remain on treatment (mira-
begron or tolterodine), switch to a treatment with efficacy
and price similar to solifenacin or discontinue (i.e. go to
‘no treatment’). A small proportion received botulinum
toxin (BTX) after this next line of therapy (this transition
was not allowed directly after mirabegron or tolterodine).
The probabilities of switch and discontinuation were
dependent on adverse events. Patients with adverse events
could stay on treatment, but incurred a disutility. Patients
who discontinued treatment could naturally improve and
thereby transition to a lower severity category after
1 month, or could worsen or stay the same. These patients
could also restart their previous treatment, could move to a
new treatment, or remain off treatment. In the event of
success on BTX, patients were assumed to move to the
lowest level of severity and remain there until the end of
the simulation.
The model accounted for the differences in probability
of improving or worsening between the short- and long-
term. Thus, the probability of improvement was greatest in
the first month after treatment initiation, after which it
decreased progressively, and was then assumed constant
after 3 months.
Several populations were considered. Any patient pre-
senting with OAB formed the base case population. Other
populations considered were patients dissatisfied with
previous treatment, patients dissatisfied with previous
treatment due to lack of efficacy, patients dissatisfied with
previous treatment due to intolerance, treatment-naı¨ve
patients, elderly patients, female patients, male patients and
incontinent patients.
2.4 Model Input Parameters
All model input parameters are presented in detail in
Supplementary Table 1.
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2.4.1 Symptom Severity
Symptoms (micturition frequency and incontinence) had
five levels of severity (Table 1). Initial proportions of
patients with symptoms of each severity were derived from
SCORPIO [15]. Transition probabilities between symptom
levels for mirabegron 50 mg and tolterodine ER 4 mg were
estimated by applying multinomial logistic regression
models to the SCORPIO trial data (see Electronic Sup-
plementary Material and Supplementary Tables 2 and 3).
2.4.2 Treatment Persistence, Switching and Restarting
Other model inputs are summarised in Table 2. Persistence
on mirabegron was extrapolated from the study of Wagg
et al. [21], in which data were extracted via medical
practice software and anonymised from the records
of [1,200,000 registered patients, of whom 4,833 had
documented OAB. An additional 12-week observational
study of OAB patients in Spain showed that 24 % of
patients who changed treatment did so because of adverse
events [22]; these results were consistent with those of a
large US survey of patients with OAB [13]. As no real-life
data are available for persistence with mirabegron, the
model assumed that discontinuation rates for patients
without adverse events were similar for mirabegron and its
comparator. The probability of switching to next-line
therapy was obtained from an analysis based on the UK
general practice research database [23]. The base-case
frequency (Table 2) was derived from 5,424 patients who
received first-line tolterodine, of whom 68.92 % discon-
tinued and 26.06 % switched to another medication (most
frequently oxybutynin).
No data are available in the literature regarding the
probability of restarting treatment after a period of no
treatment. We assumed an annual probability of 50 %
(monthly probability of 5.6 %). The 79 % probability of
improvement of symptoms after BTX injection was based
on a published cost-effectiveness analysis comparing BTX
to antimuscarinic therapy [24].
2.4.3 Adverse Events
Monthly probabilities of adverse events were derived from
SCORPIO [15]. Patients were assumed to experience dry
mouth or constipation (Table 2). Other adverse events were
excluded based on the results of a European cross-sectional
survey that showed that these two events are the main
drivers of adverse event-related treatment discontinuation
with antimuscarinic therapy [25] and the finding that the
events reported most frequently with mirabegron occur at a
similar incidence with placebo [15].
2.4.4 Utilities
Utility values according to symptom severity and adverse
events were derived from EuroQol 5-Dimension (EQ-5D)
index scores, based on the UK time trade-off tariff [26],
Fig. 1 Markov treatment
pathway. BTX botulinum toxin,
ER extended release, OAB
overactive bladder syndrome
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collected in SCORPIO [15]. A linear regression model of
EQ-5D utility as a function of symptom severity was
developed as described in detail in the Electronic Supple-
mentary Material and Supplementary Table 4. The utility
decrement for adverse events was an average, weighted
according to the treatment-specific probabilities for the
different adverse events. Utilities derived from the over-
active bladder questionnaire (OAB-q), using the algorithm
developed by Yang et al. [27], were also used.
2.4.5 Resource Utilisation and Costs
Resources and associated costs included in the model are
from a UK NHS payer perspective (Table 3). Drug therapy,
primary care visits, specialist (urologist) visits, BTX injec-
tions and incontinence pads were accounted for. Patients
were assumed to use one tablet of mirabegron per day;
wastage or partial compliance was not accounted for. Pad
utilisation was tiered according to incontinence severity.
Costs are presented in 2012 British pounds (£) and are
summarised together with sources in Table 3. An annual
discount rate of 3.5 % was applied to costs and health benefits.
2.5 Model Outputs
The model was designed to output (i) average annual
cumulative costs by treatment strategy; (ii) quality-adjusted
life-years (QALYs) gained by using a particular treatment
strategy; (iii) and incremental cost-effective ratios (ICERs)
expressed as incremental cost per QALY gained.
2.6 Sensitivity and Subgroup Analyses
Sensitivity analyses evaluated the impact of assumptions
used in the model and variability surrounding model inputs.
For deterministic sensitivity analyses, one variable or
assumption was changed at a time. One-way sensitivity
analyses were conducted on all model parameters associ-
ated with uncertainty: proportions of patients by severity
level at baseline; transition probabilities between symptom
levels; utilities by symptom level; probabilities of treat-
ment-related events; probabilities related to BTX injec-
tions; and probabilities associated with adverse events and
resource use. Outcomes were computed using confidence
limits around each parameter or other fixed values.
A probabilistic sensitivity analysis was also performed.
Appropriate statistical distributions were assigned to input
parameters (Table 2). Values were drawn at random from
statistical distributions for these variables and the process
was iterated 5,000 times to provide distributions for ICERs.
Cost-effectiveness acceptability curves (CEACs) were
generated at various willingness-to-pay (WTP) thresholds.
The probabilistic analysis was programmed in visual basic
applications for Excel.
Finally, because indirect costs were not included in the
model, a sensitivity analysis including indirect costs valued
Table 2 Model inputs for the base-case scenario. Also shown are ranges used for the probabilistic sensitivity analysis
Parameter Base case value Sensitivity analysis range References
Discontinuation and switch
Treatment discontinuation
Without AEs 6.4 % per month 3.0–14.5 % Base case and upper limit: Wagg et al. [21];
Sa´nchez-Ballester et al. [22]; lower limit: assumption
With AEs 90 % per month 50–100 % Expert opinion
Treatment switcha 26.1 % 15.3–50.0 % Base case: Odeyemi et al. [23]; sensitivity analysis:
D’Souza et al. [38]/assumption
Treatment restartb 5.6 % per month 0–20.0 % Expert opinion
BTX injection 0.01 % per month 0–0.05 % Expert opinion
Success with BTX 79 % 50–100 % Wu et al. [24]
Adverse events
Dry mouth
Mirabegron 50 mg 2.8 % 2.1–3.5 % SCORPIO [15]
Tolterodine ER 4 mg 10.1 % 8.7–11.5 % SCORPIO [15]
Constipation
Mirabegron 50 mg 1.6 % SCORPIO [15]
Tolterodine ER 4 mg 2.0 % SCORPIO [15]
AE adverse event, BTX botulinum toxin, ER extended release, OAB overactive bladder syndrome
a Among patients discontinuing OAB treatment
b Split between different medications was assumed to be one-third each for initial, second- and third-line treatments
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using the human capital approach to determine the effect
on the ICER estimate was also performed. Absenteeism
was derived from the percentage work time missed,
assessed for each patient in the SCORPIO trial using the
work productivity and activity impairment (WPAI) ques-
tionnaire [28].
Subgroup analyses were also performed.
3 Results
3.1 Base-Case Scenario
On average, patients treated with tolterodine discontinued
treatment earlier than those treated with mirabegron
(329.79 vs. 391.79 days, respectively). Total costs per
Table 3 Modelled resource use and costs for the base-case scenario. Also shown are ranges used for the probabilistic sensitivity analysis
Parameter Base case value Sensitivity analysis range References
Resource use
Pad utilisation
Incontinence level 1 0.17 0.150–0.198 SCORPIO [15]
Incontinence level 2 0.75 0.687–0.817
Incontinence level 3 1.38 1.282–1.486
Incontinence level 4 1.89 1.745–2.039
Incontinence level 5 3.34 3.167–3.511
GP consultations 1 visit at start and at every switch 0–2 Expert opinion
Specialist consultations 1.5 visits at start and at every switch 1–3 Cardozo et al. [31]/assumption
BTX injectionsa 0.17 per month 0–0.34 Expert opinion
Costs
Monthly acquisition cost
Mirabegron 50 mg £29.40 BNF 2011/12 [39]
Tolterodine ER 4 mg £28.01 BNF 2011/12 [39]
Solifenacin 5 mg £28.00 BNF 2011/12 [39]
GP consultation £36.00 PSSRU 2010 [40]
Specialist visit £96.00 NHS payment 2010–2011
BTX injection/reinjection £1,158/£964 Nottingham Urology Group [41]
Incontinence pad £0.16 AgeUK [42]
BNF British National Formulary, BTX botulinum toxin, GP general practitioner, PSSRU Personal Social Services Research Unit
a Following successful first injection
Table 4 Predicted costs (2012) and cost-effectiveness outcomes for the base-case analysis (general OAB population)
Parameter Mirabegron strategy Tolterodine strategy Cost difference/incremental change
Predicted costs (£)
Drug acquisition 451.43 343.70 107.72
Other OAB treatment 364.92 393.42 -28.50
GP visit 101.38 105.83 -4.45
Specialist visit (initial ? follow-up) 405.83 423.31 -17.78
BTX (initial ? repeat injections) 93.66 102.78 -9.11
Incontinence pads 228.70 238.71 -10.00
Total 1,645.62 1,607.75 37.88
Cost effectiveness
Total costs (£) 1,645.62 1,607.75 37.88
QALYs 3.764 3.755 0.009
ICER (£/QALY gained per patient) 4,386
BTX botulinum toxin, GP general practitioner, ICER incremental cost-effectiveness ratio, OAB overactive bladder syndrome, QALY quality-
adjusted life-year
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patient over 5 years were £1,645.62 for the mirabegron
strategy and £1,607.75 for tolterodine from the UK NHS
perspective. Medication costs were higher with mirabegron
than with tolterodine (£451.43 vs. £343.70), mainly due to
the differences in time to discontinuation (Table 4). This
was partly offset by the reduced costs of specialist visits
and incontinence pad utilisation under the mirabegron
strategy.
Based on EQ-5D utilities, the mirabegron strategy was
associated with a gain of 0.009 QALYs, and an additional
cost of £37.88 over the modelled 5-year period. The
resulting ICER was below the WTP threshold of £20,000/
QALY gained, at £4,386/QALY gained (Table 4). Based
on OAB-q utilities, the number of QALYs gained was
0.01259, leading to an ICER of £3,008/QALY gained.
3.2 Subgroup Analyses
Results of cost-effectiveness analyses for different sub-
groups are summarised in Table 5. Mirabegron was found
to be cost effective compared to tolterodine ER 4 mg in all
subgroups except the subgroup comprising men (ICER
£38,708). The benefit of mirabegron 50 mg was greatest
for patients dissatisfied because of adverse events, with an
estimated gain of 0.0186 QALYs (EQ-5D) at a cost of
£28.37 over 5 years, yielding an ICER of £1,528/QALY
gained. ICERs across the other subgroups ranged from
£3,091/QALY gained (women only) to £5,736/QALY
gained (elderly).
3.3 Deterministic Sensitivity Analysis
For the sensitivity analyses, health state utilities based on
EQ-5D were used. Detailed results are shown in the tor-
nado chart in Fig. 2. The model was most sensitive to the
transition probabilities between symptom levels of incon-
tinence and micturition for mirabegron and tolterodine, the
distribution of patients by micturition and incontinence
severity level at baseline, and the monthly probability of
restarting treatment. However, mirabegron was cost
effective or dominant compared with tolterodine in all
scenarios. The ICER was also found to vary little (from
£4,092 to 4,698/QALY gained) when the discount rate was
varied from 0 to 6.0 % for costs and outcomes.
3.4 Probabilistic Sensitivity Analysis
The probabilistic sensitivity analysis results are represented
in the CEAC shown in Fig. 3. At the WTP threshold of
£20,000/QALY gained, the probability of mirabegron
50 mg being cost effective relative to tolterodine ER 4 mg
was 89.4 %.
3.5 Sensitivity Analysis for Indirect Costs
The inclusion of indirect costs resulted in lower ICERs in
all comparisons, with mirabegron being dominant in all
populations except the previously treated and men sub-
groups, in which the ICERS were below the WTP threshold
of £20,000/QALY gained (data not shown).
4 Discussion
The base-case analysis in the present model showed that
mirabegron 50 mg/day is cost effective at the WTP
thresholds of £20,000/QALY and £30,000/QALY gener-
ally applied by the UK National Institute for Health and
Clinical Excellence [29]. The one-way deterministic sen-
sitivity analysis demonstrated that the ICER remained
below the WTP threshold of £20,000 whenever a parameter
was modified. The probabilistic sensitivity analysis, which
tested uncertainty around the model parameters through
Monte Carlo simulations using appropriate distributions,
demonstrated a high probability (89.4 %) that mirabeg-
ron 50 mg/day would be cost effective compared with
Table 5 Cost-effectiveness results by subgroup (UK NHS perspective)
Subgroup Incremental costs (£) Incremental QALYs ICER (£/QALY gained)
General population 37.88 0.0086 4,386
Previously treated 38.07 0.0099 3,836
Dissatisfied because of lack of efficacy 40.27 0.0091 4,446
Dissatisfied because of adverse events 28.37 0.0186 1,528
Incontinent 32.36 0.0124 2,620
Elderly 35.19 0.0061 5,736
Treatment naı¨ve 40.27 0.0076 5,315
Women 37.73 0.0122 3,091
Men 43.96 0.0011 38,708
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
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tolterodine ER 4 mg/day at the generally accepted cost-
effectiveness threshold of £20,000/QALY gained. Overall,
the subgroup analyses also supported the primary result.
To the best of our knowledge, no other economic
analyses of mirabegron in the treatment of OAB with
which to compare our findings are available in the litera-
ture. However, previously published cost-effectiveness
models comparing tolterodine ER 4 mg with other
antimuscarinic agents suggest that our results are plausible.
Speakman et al. [30] developed a 1-year Markov model to
evaluate the cost effectiveness of solifenacin 5 mg and
10 mg compared with tolterodine (immediate release 2 mg
twice daily or ER 4 mg daily) in OAB from the UK NHS
perspective, while a 1-year model developed by Cardozo
et al. [31] assessed the cost effectiveness of solifenacin
against other antimuscarinic agents commonly used in UK
Fig. 2 Deterministic sensitivity analysis. AE adverse event, BTX botulinum toxin, EQ5D European Quality of Life questionnaire in five
dimensions, ICER incremental cost-effectiveness ratio
Fig. 3 Cost-effectiveness
acceptability curve for
mirabegron 50 mg vs
tolterodine extended release
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clinical practice, including tolterodine. The predicted total
annual costs per patient for tolterodine were £526 and
£480, in the Speakman and Cardoza studies respectively
[30, 31], compared with an annual cost of £620 in our
model when run over a 1-year time horizon. The difference
in costs was mainly due to our assumption that all patients
initiating a new treatment would consult a specialist. The
respective numbers of QALYs for 1 year with tolterodine
were 0.705 and 0.710 [30, 31], compared with 0.814 in our
model, with the difference being due to our use of a new set
of utilities based on EQ-5D data collected in clinical trials
of mirabegron. However, the difference between the
maximum and minimum utilities in this new model is
similar to the range in the earlier model of Speakman et al.
[30] (0.145 vs. 0.144). Furthermore, the QALY gain based
on our model (0.009) is consistent with these and other
previous studies that used EQ-5D (0.004 [30], 0.014 [32]
and 0.004 [33]). This suggests that the magnitude of the
QALY gain is meaningful in OAB, although it should be
noted that as a generic tool EQ-5D is relatively insensitive
to changes in OAB symptoms. An analysis mapping EQ-
5D scores to those obtained with the OAB-specific OAB-
5D instrument has shown that scores are higher with OAB-
5D, suggesting that the magnitude of any differences would
also be higher [34].
In other analyses carried out from a UK health system
perspective, Hakkaart et al. [32] found incremental costs
per QALY gained over placebo to be £17,602 and £24,464
with solifenacin 5 mg and 10 mg daily, respectively, in a
Markov model run over a 12-month time horizon in
patients with OAB, and Getsios et al. [33] showed that a
sustained-release formulation of oxybutynin 10 mg domi-
nated immediate-release tolterodine 4 mg. Another ana-
lysis has suggested that immediate- and sustained-release
oxybutynin and tolterodine ER are all cost-effective
options for managing urge incontinence from a UK NHS
perspective [35]. These findings suggest strongly that
economic comparisons of mirabegron with these and other
antimuscarinic agents will be of considerable interest to
clinicians and healthcare policy makers. In addition to the
analysis reported here, a model based on a mixed treatment
comparison (MTC) of mirabegron and antimuscarinic
therapy for OAB has also been reported [36, 37]. This
demonstrated that the efficacy of mirabegron 50 mg in
OAB patients is similar to that of most approved antimu-
scarinic drugs in the general OAB population and that it
has the most favourable tolerability profile, with a signifi-
cantly lower incidence of dry mouth than any antimu-
scarinic agent and the same incidence of constipation as
placebo [36].
A key strength of our model is that it was designed to
capture the effects on HRQoL of variations in symptom
severity over time, as well as the impact of treatment
discontinuation and switching on costs and health out-
comes. In contrast, previous Markov models for this type
of analysis have been based on the extensively applied
model developed by Kobelt et al. [19], which consists of
five health states representing different levels of disease
severity with a single absorbing state for drop-outs, who
were considered to remain off treatment. We found that the
main symptoms of OAB (micturitions and incontinence)
had a significant influence on utility independently of each
other, with moderate correlations between changes in these
symptoms. The progression of these symptoms over time
was therefore modelled separately. In addition, we attached
increased importance to the modelling of patient pathways
after treatment discontinuation, because of the high rates of
discontinuation and treatment switching observed in
patients with OAB. Finally, the use of a 5-year time hori-
zon, at which point \5 % of patients remained on treat-
ment in the model, and performing sensitivity analyses
based on other time-points, at which the conclusions
regarding the cost-effectiveness of mirabegron held,
ensured that the model reflected the costs and outcomes of
managing a chronic condition. Therefore, we believe that
our model more accurately represents the clinical man-
agement of OAB.
Another strength is that we have analysed the cost
effectiveness of therapy in various relevant patient sub-
groups. These analyses showed that mirabegron was con-
sistently cost effective in most of these subgroups.
In contrast, possible limitations include the assumption
that discontinuation rates due to reasons other than adverse
events were similar for mirabegron and tolterodine,
because no real-life data on persistence with mirabegron
are available. We believe that this is a conservative
assumption because the MTC demonstrated that the prob-
ability of mirabegron being more effective than tolterodine
in terms of micturition and incontinence is 87.4 and
88.3 %, respectively [36]. Moreover, no data on the
probability of BTX being used to treat OAB following drug
therapy and no data on the numbers of visits to specialists
were available. Again, we took a conservative approach
and assumed that the proportions of patients receiving BTX
were small; sensitivity analysis showed that the ICER
would increase modestly if no patients received BTX and
that mirabegron remained cost effective. The impact of
varying the numbers of visits to specialists was also
assessed in a sensitivity analysis, which showed that this
affected the absolute results, but not sufficiently to change
the conclusion that mirabegron is cost effective. Further-
more, number of specialist visits was not one of the main
parameters to which the model was sensitive.
The model used in our analysis included direct health-
care costs only, in line with the requirements of UK
guidelines for pharmacoeconomic assessments. The failure
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to include indirect costs in the model represents another
potential limitation, but a sensitivity analysis including
indirect costs showed that ICERs were lower in all com-
parisons, with mirabegron being dominant in all popula-
tions except the previously treated and men subgroups.
5 Conclusion
In conclusion, from a UK NHS perspective, mirabegron
50 mg/day appears to be a cost-effective treatment strategy
compared with tolterodine ER 4 mg/day for the general
population of adults with OAB and for subgroups including
those previously treated and those who are treatment naive,
patients dissatisfied due to lack of efficacy or adverse
events, patients who are incontinent, the elderly, and
women.
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